Effects of TS-1 and heparin-based chemoradiation combined with MMC, CDDP as the neoadjuvant therapy on the patients with the potentially resectable pancreatic cancer

Effects of TS-1 and heparin-based chemoradiation combined with MMC, CDDP as the neoadjuvant therapy on the patients with the potentially resectable pancreatic cancer - Effects of TS-1 and heparin-based neoadjuvant therapy on pancreatic cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003000

Enrollment

Registered

2010-01-20

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

potentially resectable pancreatic cancer

Interventions

with neoadjuvant therapy of TS-1 and heparin-based chemoradiation before surgery with adjuvant therapy other than TS-1 and heparin-based chemoradiation during the prioperative period

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: T3 or T4 potentially resectable pancreatic cancer

Exclusion criteria

Exclusion criteria: with metastasis

Design outcomes

Primary

Measure	Time frame
overall survival	—

Countries

Japan

Contacts

Public ContactMinoru Kitago

Department of Surgery, Keio University School of Medicine Department of Surgery

contact@keio-hpbts.jp03-3353-1211(ext62529)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026